Published: February 09, 2011
Maas Biolab Wins World Cyclosporin Brain Formula Patents
ALBUQUERQUE, N.M. - (BUSINESS WIRE) - Maas Biolab received United States Patent 7,446,093, European Union
Patent 1,091,750 and Patents in India, Canada and New Zealand for
its Mitogard cyclosporin formulas. Mitogard is designed for central
nervous system delivery to treat neurodegenerative diseases, in
particular amyotrophic lateral sclerosis (ALS). The patent covers the
use of cyclosporin in DMSO formulations for neuroprotection and
immunosuppression via cerebrospinal fluid (CSF), vascular, nasal and
pulmonary delivery. The 19 European countries include Germany, France,
the United Kingdom, Italy, Spain, Netherlands, Sweden and Switzerland.
Cyclosporin formulation is a compounding challenge, since it is water
insoluble. The Maas Biolab solution is the cyclosporin-solubilizing
excipient dimethyl sulfoxide (DMSO) that has low toxicity, low viscosity
for easy syringeability, and chemical compatibility with the components
of CSF pumps, ports and catheters. Water-free, full strength,
ready-to-infuse Mitogard has low viscosity and long-term stability
within functioning pumps.
Cyclosporin does not cross the intact blood-brain barrier. Neurosurgeon
and Maas Biolab CEO Marcus Keep, M.D., created Mitogard to bypass the
blood-brain barrier with direct CSF infusion of cyclosporin to get it
into the spinal cords and brains of ALS patients. Cyclosporin is a
powerful neuroprotectant in the G93A mouse model of ALS, slowing loss of
motor neurons and paralysis. Long-term therapy with very low-dose CSF
cyclosporin is not expected to be systemically immunosuppressive nor
nephrotoxic. Maas Biolab has FDA Orphan Drug Designation for cyclosporin
treating ALS, and is conducting NIH-funded animal toxicity trials of
Mitogard.
Maas Biolab, LLC
Maas Biolab is a private pharmaceutical company in Albuquerque, New
Mexico, USA, developing Mitogard, the only cyclosporin formula designed
for CSF delivery, to treat amyotrophic lateral sclerosis (ALS) and other
neurodegenerative diseases. (http://www.maasbiolab.com)
Maas Biolab
Michael Vickers, 505-843-4230
michael@maasbiolab.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
